Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter CTLA-4 (Tremelimumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal unconjugated Recombinant Antibody
Produktnummer ABIN7200670
  • Target
    CTLA-4 (Tremelimumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    Maus
    Klonalität
    Monoklonal
    Applikation
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Tremelimumab Biosimilar, Human CTLA-4 monoclonal antibody
    Spezifität
    The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4.
    Produktmerkmale
    Recombinant Chimeric IgG2 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The anti-human CTLA-4 monoclonal antibody tremelimumab biosimilar (research grade) was produced in mammalian cells.
    Isotyp
    IgG2, kappa
  • Applikationshinweise
    ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by tremelimumab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    CTLA-4 (Tremelimumab Biosimilar)
    Substanzklasse
    Biosimilar
    Hintergrund
    What is Tremelimumab biosimilar research grade? Tremelimumab (formerly ticilimumab) is a fully human monoclonal antibody against CTLA-4 / CD152. It is an immune checkpoint blocker. Unlike Ipilimumab (another fully human anti-CTLA-4 / CD152 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.Tremelimumab Biosimilar uses the same protein sequences as the therapeutic antibody tremelimumab.

    Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade.

    Tremelimumab binds to the protein CTLA-4 / CD152, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4 / CD152, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.
Sie sind hier:
Kundenservice